[Rimonabant. Risk of depression has not been finally clarified].
Barbara
B
Kreutzkamp
D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D063387:Cannabinoid Receptor Antagonists; D003866:Depressive Disorder / Q000139:chemically induced* / Q000523:psychology; D006801:Humans; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D012306:Risk
D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant